


# THE COMBINATION TREATMENTS CHALLENGE



## WHAT ARE COMBINATION TREATMENTS?

Combination treatments combine **two or more individual treatments.**



Many combination treatments combine a “**backbone**” treatment with a new “**add-on**” treatment.

**Backbone treatment:** a treatment or treatment combination that is already available to patients.

**Add-on treatment:** a treatment or treatment combination, that is added to the existing backbone treatment.


The backbone and add-on treatments are often produced by different manufacturers, so compliant collaboration is essential to ensure patients benefit from combination treatments.



## THE IMPORTANCE OF COMBINATION TREATMENTS



We know from experience in complex diseases, such as **cancer, HIV, rheumatoid arthritis** and **Hepatitis C**, that combination treatments have the potential to deliver significant clinical benefits to patients.



This is because using multiple treatments in combination can **simultaneously target numerous pathways** that drive a disease.




As the understanding of complex diseases increases, **combination treatments are becoming increasingly common** to improve patient survival and quality of life.



## THE CHALLENGE

Despite potentially delivering **significant clinical benefits to patients**, combination treatments often face cost effectiveness barriers even if the new add-on treatment were to be given away at zero price.

The use of combination treatments can potentially extend the lives of patients. So, **even if the add-on treatment were to be given away at zero price, the cost to the healthcare system could still increase** due to the backbone treatment being used for longer.



As treatments included within a combination are often developed by different manufacturers, they tend to be priced independently of each other. Intercompany discussions on price are not permitted, as companies are not legally allowed to work together to make pricing decisions due to strict competition law in the UK.

IN 2019, ONLY **56%**

of licensed combination treatments are routinely available to patients on the NHS, in the UK.<sup>1</sup>



There is consensus within key stakeholder groups, nationally and internationally, that **solutions for accessing combination treatments need to be found** quickly for the benefit of patient outcomes, now and in the future.



## TAKEDA'S PROPOSED SOLUTION



Takeda is guided by an unwavering commitment to **put the patient first** in everything that we do.



In partnership with experts from academia, clinical and patient communities, and with expert input from NICE and the NHS, we have developed a proposed solution that has the potential to improve patient access to combination treatments.

The solution is explained within two Whitepapers which aim to contribute to the options being explored by other stakeholders to find transactable and implementable solutions that align with current NICE appraisal and NHS England commercial methods.

The **Value Attribution Framework** proposes an economic methodology that defines a fair division of value across the treatments in a combination.

The **Voluntary Arbitration Framework** proposes a standard operating procedure to support compliant dialogue and agreement between pharmaceutical companies on the value attributed to each treatment within a combination.

Takeda recognises the importance of collaboration. We encourage feedback, critique, and debate of the two Whitepapers so that we can contribute an implementable solution that represents perspectives from all stakeholders.

To find out more, visit [www.takeda.com/en-gb/what-we-do/combination-treatments](http://www.takeda.com/en-gb/what-we-do/combination-treatments) or contact the team on [combinationmedicinesUK@takeda.com](mailto:combinationmedicinesUK@takeda.com).

<sup>1</sup> EFPIA and IQVIA., EFPIA Patients W.A.I.T. Indicator 2019 Survey. EFPIA. 2020. Pg 49

